PLSE

Pulse Biosciences, Inc. develops and commercializes proprietary Nano-Pulse Stimulation (NPS) technology, a novel energy modality that delivers nanosecond-duration pulses of electrical energy to non-thermally clear cells while preserving the surrounding architecture. Headquartered in Hayward, California, the company focuses on dermatology and medical aesthetics applications. Its flagship product, CellFX System, received FDA clearance in 2021 for the treatment of seborrheic keratosis, a common non-cancerous skin lesion. Pulse Biosciences targets the dermatology market with its proprietary platform technology, which creates cellular disruption through an electrical field rather than thermal damage associated with traditional ablation methods. The company operates as a commercial-stage medical technology firm, having transitioned from development to market adoption of its NPS technology. In 2023, Pulse Biosciences expanded its product portfolio with additional FDA clearances for the CellFX System to treat skin lesions and general dermatological procedures. The company collaborates with dermatologists and plastic surgeons to establish clinical evidence and expand its commercial footprint in the aesthetic and therapeutic dermatology sectors. Pulse Biosciences holds an extensive intellectual property portfolio with numerous patents covering its NPS technology platform. As a growth-stage company, it continues to invest in clinical studies, regulatory approvals, and commercial infrastructure to support broader adoption of its technology across dermatological applications.